MX2023007575A - Tratamiento de la migraña. - Google Patents
Tratamiento de la migraña.Info
- Publication number
- MX2023007575A MX2023007575A MX2023007575A MX2023007575A MX2023007575A MX 2023007575 A MX2023007575 A MX 2023007575A MX 2023007575 A MX2023007575 A MX 2023007575A MX 2023007575 A MX2023007575 A MX 2023007575A MX 2023007575 A MX2023007575 A MX 2023007575A
- Authority
- MX
- Mexico
- Prior art keywords
- migraine
- patients
- treatment
- present disclosure
- disclosure provides
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title abstract 3
- 206010027599 migraine Diseases 0.000 title abstract 3
- 230000001154 acute effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=CC=CC=C1 DDOOFTLHJSMHLN-ZQHRPCGSSA-N 0.000 abstract 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 abstract 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 abstract 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 abstract 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 abstract 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 229950001679 ubrogepant Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Abstract
La presente descripción proporciona métodos para el tratamiento agudo de la migraña con o sin aura, que comprenden la administración de ubrogepant. En particular, la presente descripción proporciona métodos para el tratamiento agudo de la migraña en pacientes que tienen insuficiencia hepática; en pacientes con insuficiencia renal; y en pacientes que toman de manera concurrente moduladores de CYP3A4 o inhibidores solo de BCRP y/o P-gp.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063129379P | 2020-12-22 | 2020-12-22 | |
PCT/US2021/064853 WO2022140537A1 (en) | 2020-12-22 | 2021-12-22 | Treatment of migraine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007575A true MX2023007575A (es) | 2023-09-21 |
Family
ID=82021866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007575A MX2023007575A (es) | 2020-12-22 | 2021-12-22 | Tratamiento de la migraña. |
Country Status (5)
Country | Link |
---|---|
US (3) | US11717515B2 (es) |
AU (1) | AU2021409718A1 (es) |
CA (1) | CA3206184A1 (es) |
MX (1) | MX2023007575A (es) |
WO (1) | WO2022140537A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
MX2023007575A (es) | 2020-12-22 | 2023-09-21 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US6103260A (en) | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
EP1613368B1 (en) | 2003-03-14 | 2011-11-30 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin cgrp receptor antagonists |
CA2519515A1 (en) | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
DE602005020656D1 (de) | 2004-09-13 | 2010-05-27 | Merck Sharp & Dohme | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors |
US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
DE102004063755A1 (de) | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
EP1861399B1 (en) | 2005-03-14 | 2011-12-14 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
BRPI0707584A2 (pt) | 2006-02-09 | 2011-05-10 | Merck & Co Inc | composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica |
EP2024358B1 (en) | 2006-05-09 | 2014-11-05 | Merck Sharp & Dohme Corp. | Substituted spirocyclic cgrp receptor antagonists |
CA2689217C (en) | 2007-06-05 | 2016-02-16 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
WO2009050234A1 (de) | 2007-10-18 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Cgrp-antagonisten |
WO2009065922A2 (de) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Organische verbindungen |
CA2722536A1 (en) | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
WO2010139717A1 (de) | 2009-06-05 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Neue verbindungen |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
TWI501968B (zh) | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
US8883807B2 (en) | 2010-11-12 | 2014-11-11 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane CGRP receptor antagonists |
WO2013066360A1 (en) | 2010-12-22 | 2013-05-10 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide cgrp receptor antagonists |
US8895572B2 (en) | 2010-12-22 | 2014-11-25 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide CGRP receptor antagonists |
CN103491964A (zh) | 2011-03-08 | 2014-01-01 | 扎里卡斯药品有限公司 | 固体分散体制剂及其使用方法 |
WO2012129013A1 (en) | 2011-03-18 | 2012-09-27 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
WO2013036861A1 (en) | 2011-09-08 | 2013-03-14 | Codexis, Inc | Biocatalysts and methods for the synthesis of substituted lactams |
EP4019516A1 (en) | 2012-03-14 | 2022-06-29 | Merck Sharp & Dohme Corp. | Asymmetric phase transfer catalysis |
US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
WO2013162769A1 (en) | 2012-04-25 | 2013-10-31 | Centric Research Institute | Sensitization composition and method of use |
EP2846801B1 (en) | 2012-05-09 | 2017-04-05 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
WO2013169567A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
EP2846798B1 (en) | 2012-05-09 | 2018-04-04 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
CN105142730B (zh) | 2013-03-15 | 2019-04-16 | 通尼克斯制药有限公司 | 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂 |
MX2016003394A (es) | 2013-09-16 | 2016-10-28 | Merck Sharp & Dohme | Formulaciones para antagonistas del receptor del cgrp. |
WO2015120014A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
CN106456662A (zh) | 2014-02-24 | 2017-02-22 | 奥利金制药公司 | 口服给药的戊聚糖多硫酸盐的组合物及其使用方法 |
CA2955495C (en) | 2014-08-22 | 2023-09-19 | Jeffrey Etter | High dosage strength tablets of rucaparib |
EP3247352B1 (en) * | 2015-01-23 | 2020-06-24 | Grünenthal GmbH | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
CN108473560A (zh) | 2015-09-24 | 2018-08-31 | 泰瓦制药国际有限公司 | 预防、治疗和减轻(持续性)创伤后头痛 |
US20180092899A1 (en) * | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
KR20190133174A (ko) | 2017-03-02 | 2019-12-02 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 칼시토닌 유전자 관련 펩티드에 대해 지시되는 항체에 반응하는 두통 환자를 선택하는 방법 |
TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
US20190374518A1 (en) * | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
EP3956025A1 (en) | 2019-04-18 | 2022-02-23 | Allergan Sales, LLC | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
CA3156009A1 (en) | 2019-09-25 | 2021-04-01 | Allergan Pharmaceuticals International Limited | POLYTHERAPY WITH CGRP ANTAGONISTS |
JP2023535744A (ja) | 2020-07-29 | 2023-08-21 | アラーガン ファーマシューティカルズ インターナショナル リミテッド | 片頭痛の治療 |
MX2023007575A (es) | 2020-12-22 | 2023-09-21 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
US20230130736A1 (en) | 2021-09-27 | 2023-04-27 | Allergan Pharmaceuticals International Limited | Methods of treating migraine |
-
2021
- 2021-12-22 MX MX2023007575A patent/MX2023007575A/es unknown
- 2021-12-22 US US17/559,177 patent/US11717515B2/en active Active
- 2021-12-22 AU AU2021409718A patent/AU2021409718A1/en active Pending
- 2021-12-22 WO PCT/US2021/064853 patent/WO2022140537A1/en active Application Filing
- 2021-12-22 CA CA3206184A patent/CA3206184A1/en active Pending
-
2023
- 2023-06-16 US US18/210,719 patent/US11857542B2/en active Active
- 2023-11-29 US US18/523,481 patent/US20240100029A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240100029A1 (en) | 2024-03-28 |
AU2021409718A9 (en) | 2024-02-08 |
US20220193051A1 (en) | 2022-06-23 |
US20230330072A1 (en) | 2023-10-19 |
CA3206184A1 (en) | 2022-06-30 |
US11857542B2 (en) | 2024-01-02 |
US11717515B2 (en) | 2023-08-08 |
AU2021409718A1 (en) | 2023-07-13 |
WO2022140537A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007575A (es) | Tratamiento de la migraña. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
CL2009000843A1 (es) | Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet. | |
MX2022001075A (es) | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2012004741A (es) | Apremilast para el tratamiento de sarcoidosis. | |
MX2018013762A (es) | Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso. | |
MX2020009668A (es) | Métodos novedosos. | |
TW200716159A (en) | Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells | |
NO20072890L (no) | Behandling av mastitt | |
ATE485832T1 (de) | Glucoseisomerase zur behandlung von fructose- unverträglichkeit | |
WO2018187698A3 (en) | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists | |
MX2020014159A (es) | Estructuras porosas cargables para usarse como implantes. | |
NO20076120L (no) | Stabile nanopartikkelformuleringer | |
MX2019014771A (es) | Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña. | |
WO2018067946A8 (en) | METHODS OF TREATING PATIENTS USING RETINOIC ACID ALPHA RECEPTOR AGONIST AND ANTI-CD38 ANTIBODY | |
WO2020008489A3 (en) | Aptamers for use in the therapy, prevention, diagnosis and detection of the papillomavirus | |
MX2023011202A (es) | Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds). | |
DK2155179T3 (da) | Axomadol til smertebehandling arthrose | |
MX2022006045A (es) | Metodos de administracion de voxelotor. | |
PL423673A1 (pl) | Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis | |
MX2020006272A (es) | Metodos para tratar la enfermedad de gaucher. | |
CR20210463A (es) | Inhibidores de arginasa y métodos de uso de estos | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase |